Core Viewpoint - Meizhong Jiahe (02453) has received approval for its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its competitive advantage in the oncology field [2][4]. Group 1: Company Developments - Meizhong Jiahe's stock price increased by 8.67%, reaching HKD 2.13, with a trading volume of HKD 664,600 [2][4]. - The approval allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [2][4]. - This qualification positions the company as a specialized oncology medical institution with the capability to introduce innovative drugs and devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [2][4]. Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key implementation measure of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [2][4]. - The initiative aims to facilitate the use of clinically necessary drugs and advanced medical devices in designated institutions within the Greater Bay Area, enhancing healthcare access for patients [2][4].

Core Viewpoint - Meizhong Jiahe (02453) has seen a significant stock price increase of 6.12%, reaching HKD 2.08, following the announcement of its subsidiary Guangzhou Taihe Oncology Hospital being approved to enter the "Hong Kong-Macao Drug and Medical Device Access" list, enhancing its competitive edge in the oncology sector [1] Group 1 - The approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [1] - The initiative is part of the core implementation measures of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan," which aims to facilitate the use of clinical urgently needed drugs and advanced medical devices in designated medical institutions [1]

Core Points - The Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration have released the fourth batch of designated medical institutions under the "Hong Kong-Macao Medical Device and Drug Access" policy, bringing the total to 71 institutions [1] - A total of 140 types of Hong Kong and Macao drugs and medical devices have been approved for use, benefiting approximately 17,000 patients [1] - The policy allows designated medical institutions in the Greater Bay Area to use urgently needed drugs and advanced medical devices that have been approved in Hong Kong and Macao [1] Group 1 - The fourth batch of designated medical institutions includes 27 new hospitals, with 44 hospitals passing the qualification review, and one hospital removed due to closure [1] - Notable new hospitals include Southern Medical University Zhujiang Hospital, Guangzhou Medical University Affiliated Brain Hospital, and Guangdong Second People's Hospital [1] - The "Hong Kong-Macao Medical Device and Drug Access" initiative was officially implemented in 2021, with three previous batches of designated institutions announced in August 2021, February 2023, and September 2024 [2] Group 2 - Local administrative departments are required to strengthen supervision and management of designated medical institutions [2] - Designated institutions are encouraged to deepen cooperation with Hong Kong and Macao in medical services and clinical research [2] - The initiative aims to ensure that imported Hong Kong and Macao medical devices and drugs are used solely for specific medical purposes within the institutions, ensuring safety in their use [2]

Core Viewpoint - The Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration announced the fourth batch of designated medical institutions under the "Hong Kong-Macao Drug and Medical Device Access" program, bringing the total to 71 designated institutions in the Greater Bay Area [2]. Group 1: Designated Medical Institutions - The fourth batch includes 27 newly designated hospitals, with 44 hospitals passing the qualification review, and one hospital removed from the list due to closure [2]. - The designated hospitals are authorized to use urgently needed drugs and advanced medical devices that have been approved for use in Hong Kong and Macao [2]. Group 2: Program Implementation and Impact - The "Hong Kong-Macao Drug and Medical Device Access" program was officially implemented in Guangdong Province in 2021, with three previous batches of designated institutions announced in August 2021, February 2023, and September 2024 [2]. - A total of 140 varieties of Hong Kong and Macao drugs and medical devices have been approved for introduction and use, benefiting approximately 17,000 patients [2].

Core Points - The "Hong Kong-Macao Drug and Medical Device Pass" has designated a total of 71 medical institutions in Guangdong Province as of December 8, 2023 [1][2] - The fourth batch of designated hospitals includes 27 new medical institutions, such as the Southern Medical University Zhujiang Hospital [1] - Since the implementation of the "Hong Kong-Macao Drug and Medical Device Pass" in 2021, a total of 140 varieties of drugs and medical devices have been approved for import, benefiting approximately 17,000 patients [2] Summary by Sections Implementation and Designation - The "Hong Kong-Macao Drug and Medical Device Pass" was officially implemented in Guangdong Province in 2021, with the first three batches of designated medical institutions announced in August 2021, February 2023, and September 2024 [2] - The recent announcement includes 27 new hospitals, bringing the total to 71 designated institutions [1][2] Regulatory and Operational Aspects - The Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration have mandated that designated medical institutions enhance supervision and management, deepen cooperation with Hong Kong and Macao in medical services, and ensure the safety of imported drugs and medical devices [1] - The institutions are required to continuously improve the relevant systems of the "Hong Kong-Macao Drug and Medical Device Pass" [1] Patient Impact - The approved imports include 63 types of drugs and 77 types of medical devices, which have collectively served around 17,000 patients [2]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1: Regulatory Approval - Guangzhou Taihe Oncology Hospital received approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration on December 8, 2025, to be included in the designated medical institution list for the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key measure under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] Group 2: Business Expansion - The qualification allows the company to import and use urgently needed drugs and advanced medical devices that have been approved in Hong Kong and Macao but not yet in mainland China [1] - This move will enable the company to introduce innovative oncology drugs and expand its business boundaries, creating a differentiated competitive advantage in the oncology market [1] Group 3: Clinical and Research Enhancement - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, improving clinical diagnosis and treatment levels as well as research capabilities [1] - By introducing cutting-edge medical devices and optimizing oncology treatment plans, the company aims to align with international medical standards and enhance the overall patient service experience and treatment outcomes [1]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification enables the company to be recognized as a professional oncology medical institution with the capability to utilize innovative drugs and medical devices from Hong Kong and Macao, thereby broadening its business scope [1] - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, enhancing clinical diagnosis and treatment levels, and accelerating alignment with international medical standards [1] Group 2 - The introduction of cutting-edge drugs and medical devices is expected to optimize oncology treatment plans and improve patient service experience and treatment outcomes [1] - The company aims to provide urgently needed medications for more oncology patients, reinforcing its competitive edge in the oncology medical field [1]

Core Viewpoint - The company, Meizhong Jiahe (02453.HK), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macau Medical Device and Drug Access" list, enhancing its capabilities in oncology treatment and expanding its competitive edge in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed clinical drugs and advanced medical devices that are already available in Hong Kong and Macau but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the ability to utilize innovative drugs and devices from Hong Kong and Macau, thereby broadening its business scope and creating a differentiated competitive advantage in the oncology sector [1] - The initiative will facilitate deeper integration with Hong Kong and Macau's medical resources, enhancing clinical treatment levels and research capabilities, while also optimizing cancer treatment plans and aligning with international medical standards [1]

本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 公司獲批進入「港澳藥械通」指定醫療機構名單 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院於2025年12月8日，獲廣東省 衛生健康委員會與廣東省藥品監督管理局批准進入粵港澳大灣區「港澳藥械通」指 定醫療機構名單。 「港澳藥械通」是《粵港澳大灣區藥品醫療器械監管創新發展工作方案》的核心落地 舉措，進入名單的粵港澳大灣區的指定醫療機構，可經審批進口使用粵港澳大灣 區專項醫藥政策，允許指定醫療機構經審批使用港澳已上市的臨床急需藥品及具 有先進性的醫療器械。 本 ...

Core Viewpoint - The Guangdong Provincial Health Commission has announced the fourth batch of designated medical institutions under the "Hong Kong-Macao Medical Device Pass" initiative, adding 27 new institutions and removing 1 [1]. Group 1: Designated Medical Institutions - A total of 27 new medical institutions have been added to the designated list for the "Hong Kong-Macao Medical Device Pass" [1]. - One institution, the Foshan Hima Lin Shun Chao Eye Hospital, has been removed from the designated list [1]. Group 2: Institutional Details - The newly added institutions include various hospitals across Guangdong, such as: - South Medical University Eighth Affiliated Hospital, located in Shunde District, Foshan [2]. - Huizhou First People's Hospital, located in Huizhou City [2]. - Dongguan People's Hospital, located in Dongguan City [2]. - The list includes hospitals of different levels, primarily classified as tertiary and secondary hospitals [2].